The secretion of many gastrointestinal hormones is known to be altered after bariatric surgery and as one of the proglucagon-derived proteins, glicentin has recently been given new possibilities to be studied using the specific Mercodia Glicentin ELISA.
Bariatric surgery is today the most efficacious treatment for obesity with beneficial effects on glucose homeostasis, which in many cases leads to the resolution of diabetes. The secretion of many gastrointestinal hormones is known to be altered after bariatric surgery and as one of the proglucagon-derived proteins, glicentin has recently been given new possibilities to be studied using the specific Mercodia Glicentin ELISA.
The Mercodia Glicentin ELISA has been used in two studies showing a novel potential for glicentin as a biomarker predicting weight loss after bariatric surgery (1,2). The studies find that enhanced postprandial glicentin levels early after bariatric surgery correlates with the amount of weight loss 12 and 18 months after surgery, suggesting glicentin to be a potential biomarker in these patients.
Furthermore, the results encourage more studies investigating the functional properties of glicentin and its role in metabolic diseases, because it is still a rather unexplored protein.
Could glicentin levels predict which patients that need additional treatment or support after surgery in order to reach the desired effect?
- Perakakis, N. et al. Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. Metabolism. 101, 153997 (2019).
- Nielsen, M. S. et al. Oxyntomodulin and glicentin may predict the effect of bariatric surgery on food preferences and weight loss. J. Clin. Endocrinol. Metab. (2020)